5-((2-methoxyethoxy)carbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid | 74936-76-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-((2-methoxyethoxy)carbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid
• 英文别名: 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-(2-methoxyethyl) ester；5-(2-methoxyethoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid
• CAS: 74936-76-8
• 化学式: C₁₈H₂₀N₂O₇
• 分子量: 376.366
• InChiKey: MTLIBDLYSVXMIM-UHFFFAOYSA-N

物化性质

• 沸点：
  543.0±50.0 °C(Predicted)
• 密度：
  1.314±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  131
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  5-((2-methoxyethoxy)carbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid 以26%的产率得到
  参考文献：
  名称：

  Ogawa Toshihisa, Nakazato Atsuro, Tsuchida Katsuharu, Hatayama Katsuo, Chem. and Pharm. Bull., 41 (1993) N 1, S 108-116

  摘要：

  DOI：
• 作为产物：
  描述：

  3-硝基苯叉基乙酰乙酸甲氧乙酯 在 sodium hydroxide 作用下， 以 异丙醇 、 丙酮 为溶剂， 反应 5.0h， 生成 5-((2-methoxyethoxy)carbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid
  参考文献：
  名称：

  Synthesis and Antihypertensive Activities of New 1,4-Dihydropyridine Derivatives Containing a Nitrooxy Moiety at the 3-Ester Position.

  摘要：

  研究合成了一系列在3-酯位含有硝氧基的二氢吡啶类新化合物。这些化合物的降压活性经检验并与尼非地平相比较；其中一些相对具有较强的活性。同时还讨论了结构与活性之间的关系。

  DOI：

  10.1248/cpb.41.108

文献信息

• Mild and Facile Cleavage of 2-Cyanoethyl Ester Using Sodium Sulfide or Tetrabutylammonium Fluoride. Synthesis of 1,4-Dihydropyridine Monocarboxylic Acids and Unsymmetrical 1,4-Dihydropyridine Dicarboxylates.
  作者：Toshihisa OGAWA、Katsuo HATAYAMA、Hiroshi MAEDA、Yasuyuki KITA

  DOI：10.1248/cpb.42.1579

  日期：——

  Several 3-(2-cyanoethyl)-1, 4-dihydropyridine carboxylates (16) were prepared in moderate to good yields by means of the Hantzsch reaction. Treatment of these carboxylates with a weak base such as sodium sulfide or tetrabutylammonium fluoride at room temperature afforded smoothly the corresponding 1, 4-dihydropyridine monocarboxylic acids (18) in good yields. The monocarboxylic acids 18n and 18o were esterified with 2-nitrooxypropanol or N-(2-hydroxyethyl)nicotinamide p-toluenesulfonic acid salt to afford the selective coronary vasodilators CD-349 (5) and CD-832 (6), respectively.

  通过 Hantzsch 反应，制备出了几种 3-(2-氰乙基)-1,4-二氢吡啶羧酸盐 (16)，收率从中等到良好。在室温下用弱碱（如硫化钠或四丁基氟化铵）处理这些羧酸盐，可以顺利地得到相应的 1，4-二氢吡啶单羧酸（18），收率良好。单羧酸 18n 和 18o 与 2-硝基氧丙醇或 N-（2-羟乙基）烟酰胺对甲苯磺酸盐进行酯化，分别得到选择性冠状血管扩张剂 CD-349 (5) 和 CD-832 (6)。
• Process of Preparing Guanylate Cyclase C Agonists
  申请人：Bai Juncai

  公开号：US20140155575A1

  公开（公告）日：2014-06-05

  The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.

  该发明提供了制备包括从本文所述的SEQ ID NOs：1-249中选择的GCC激动剂序列的肽的过程。
• DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS
  申请人：Talley John

  公开号：US20090186834A1

  公开（公告）日：2009-07-23

  Various azetidinone, pyrrolidine, imidazolidine, and oxazolidine derivatives are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described.

  本文描述了各种吡咯烷、咪唑啉和噁唑烷衍生物，以及含有这些化合物的药物组合物和使用这些化合物治疗疾病的方法。还描述了其他实施方式。
• ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME
  申请人：SYNERGY PHARMACEUTICALS, INC.

  公开号：US20160145307A1

  公开（公告）日：2016-05-26

  The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.

  本发明提供了一种从本文描述的SEQ ID NOs:1-251所选的包含GCC激动剂序列的肽的纯化过程。该过程包括在冷冻干燥（冻干）步骤之前进行溶剂交换步骤。
• Optical active 1,4-dihydropyridine derivates
  申请人：FUJIREBIO INC.

  公开号：EP0403957A2

  公开（公告）日：1990-12-27

  Optical active 1,4-dihydropyridine derivatives of formula: wherein Ar¹ represents an aromatic hydrocarbon group or an aromatic heteromonocyclic or heterobicyclic group containing therein 1 to 3 atoms selected from the group consisting of oxygen, sulfur and nitrogen; R¹ represents a hydrocarbon group which may have one or more substituents; A represents (i) a straight chain or branched chain unsaturated hydrocarbon group, (ii) a cyclic unsaturated hydrocarbon group, or (iii) a group selected from the group consisting of -R-O-N=CH-, -R-N=N-, -R-CH=N- and -R-N=CH-, in which R is an alkylene group having 1 to 6 carbon atoms; B represents an alkylene or alkenylene group having 1 to 3 carbon atoms, which may have a substituent; Ar² represents an aromatic hydrocarbon group or a heterocyclic group; Ar³ represents a heterocyclic group which may have one or more substituents; and n is 0 or 1, and * indicates an optically active cite.

  式中具有光学活性的 1,4-二氢吡啶衍生物： 其中 Ar¹ 代表芳香烃基团或芳香杂单环基团或杂环基团，其中包含 1 至 3 个原子，这些原子选自由氧、硫和氮组成的组；R¹ 代表烃基团，可以有一个或多个取代基；A 代表(i)直链或支链不饱和烃基，(ii)环状不饱和烃基，或(iii)选自-R-O-N=CH-、-R-N=N-、-R-CH=N-和-R-N=CH-的基团，其中 R 是具有 1 至 6 个碳原子的亚烷基；Ar² 代表芳香烃基团或杂环基团；Ar³ 代表杂环基团，可带有一个或多个取代基；n 为 0 或 1，* 表示光学活性引物。